New hope for tough blood cancers: early trial tests BT02
Disease control
Not yet recruiting
This early-stage study aims to test the safety and early effectiveness of an investigational drug called BT02 for adults with blood cancers that have returned or not responded to previous treatments. Participants will receive BT02 through an IV every few weeks for up to two years…
Phase: PHASE1, PHASE2 • Sponsor: Biotroy Therapeutics • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC